nodes	percent_of_prediction	percent_of_DWPC	metapath
Naproxen—migraine—Prednisone—chronic obstructive pulmonary disease	0.179	0.508	CpDpCtD
Naproxen—CYP1A2—chronic obstructive pulmonary disease	0.175	0.634	CbGaD
Naproxen—osteoarthritis—Prednisone—chronic obstructive pulmonary disease	0.173	0.492	CpDpCtD
Naproxen—ALB—chronic obstructive pulmonary disease	0.101	0.366	CbGaD
Naproxen—PTGS1—Montelukast—chronic obstructive pulmonary disease	0.0381	0.178	CbGbCtD
Naproxen—SLCO1A2—Prednisolone—chronic obstructive pulmonary disease	0.0323	0.151	CbGbCtD
Naproxen—SLCO1A2—Prednisone—chronic obstructive pulmonary disease	0.0305	0.143	CbGbCtD
Naproxen—CYP2C8—Montelukast—chronic obstructive pulmonary disease	0.022	0.103	CbGbCtD
Naproxen—CYP2C9—Arformoterol—chronic obstructive pulmonary disease	0.0202	0.0947	CbGbCtD
Naproxen—CYP2C9—Formoterol—chronic obstructive pulmonary disease	0.0202	0.0947	CbGbCtD
Naproxen—CYP1A2—Aminophylline—chronic obstructive pulmonary disease	0.0191	0.0894	CbGbCtD
Naproxen—ALB—Prednisone—chronic obstructive pulmonary disease	0.0158	0.0738	CbGbCtD
Naproxen—CYP2C9—Montelukast—chronic obstructive pulmonary disease	0.0153	0.0718	CbGbCtD
Naproxen—Nabumetone—MPO—chronic obstructive pulmonary disease	0.000764	0.262	CrCbGaD
Naproxen—Nabumetone—CYP1A2—chronic obstructive pulmonary disease	0.000442	0.151	CrCbGaD
Naproxen—Indomethacin—CXCL8—chronic obstructive pulmonary disease	0.000368	0.126	CrCbGaD
Naproxen—Agomelatine—CYP1A2—chronic obstructive pulmonary disease	0.0003	0.103	CrCbGaD
Naproxen—Ketoprofen—CXCL8—chronic obstructive pulmonary disease	0.000295	0.101	CrCbGaD
Naproxen—Ibuprofen—CXCL8—chronic obstructive pulmonary disease	0.00029	0.0992	CrCbGaD
Naproxen—Fenoprofen—ALB—chronic obstructive pulmonary disease	0.00013	0.0444	CrCbGaD
Naproxen—Indomethacin—ALB—chronic obstructive pulmonary disease	9.57e-05	0.0328	CrCbGaD
Naproxen—Flurbiprofen—ALB—chronic obstructive pulmonary disease	8.46e-05	0.029	CrCbGaD
Naproxen—Muscular weakness—Prednisolone—chronic obstructive pulmonary disease	8.35e-05	0.000751	CcSEcCtD
Naproxen—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	8.35e-05	0.000751	CcSEcCtD
Naproxen—Skin disorder—Formoterol—chronic obstructive pulmonary disease	8.35e-05	0.000751	CcSEcCtD
Naproxen—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	8.32e-05	0.000749	CcSEcCtD
Naproxen—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	8.28e-05	0.000745	CcSEcCtD
Naproxen—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	8.26e-05	0.000743	CcSEcCtD
Naproxen—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	8.24e-05	0.000742	CcSEcCtD
Naproxen—Abdominal distension—Prednisolone—chronic obstructive pulmonary disease	8.24e-05	0.000741	CcSEcCtD
Naproxen—Sepsis—Prednisone—chronic obstructive pulmonary disease	8.23e-05	0.00074	CcSEcCtD
Naproxen—Skin disorder—Montelukast—chronic obstructive pulmonary disease	8.18e-05	0.000736	CcSEcCtD
Naproxen—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	8.12e-05	0.00073	CcSEcCtD
Naproxen—Oedema—Salbutamol—chronic obstructive pulmonary disease	8.12e-05	0.00073	CcSEcCtD
Naproxen—Infection—Salbutamol—chronic obstructive pulmonary disease	8.06e-05	0.000725	CcSEcCtD
Naproxen—Hypotension—Formoterol—chronic obstructive pulmonary disease	8.03e-05	0.000723	CcSEcCtD
Naproxen—Hypotension—Arformoterol—chronic obstructive pulmonary disease	8.03e-05	0.000723	CcSEcCtD
Naproxen—PTGS2—leg—chronic obstructive pulmonary disease	8.03e-05	0.165	CbGeAlD
Naproxen—Pancreatitis—Prednisolone—chronic obstructive pulmonary disease	8.03e-05	0.000722	CcSEcCtD
Naproxen—Pruritus—Aminophylline—chronic obstructive pulmonary disease	7.99e-05	0.000719	CcSEcCtD
Naproxen—Shock—Salbutamol—chronic obstructive pulmonary disease	7.98e-05	0.000718	CcSEcCtD
Naproxen—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	7.96e-05	0.000716	CcSEcCtD
Naproxen—Thrombophlebitis—Prednisone—chronic obstructive pulmonary disease	7.95e-05	0.000715	CcSEcCtD
Naproxen—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	7.92e-05	0.000713	CcSEcCtD
Naproxen—Diabetes mellitus—Prednisone—chronic obstructive pulmonary disease	7.91e-05	0.000712	CcSEcCtD
Naproxen—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	7.88e-05	0.000709	CcSEcCtD
Naproxen—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	7.85e-05	0.000706	CcSEcCtD
Naproxen—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	7.85e-05	0.000706	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	7.83e-05	0.000704	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	7.83e-05	0.000704	CcSEcCtD
Naproxen—Insomnia—Formoterol—chronic obstructive pulmonary disease	7.77e-05	0.000699	CcSEcCtD
Naproxen—Insomnia—Arformoterol—chronic obstructive pulmonary disease	7.77e-05	0.000699	CcSEcCtD
Naproxen—Anorexia—Salbutamol—chronic obstructive pulmonary disease	7.74e-05	0.000696	CcSEcCtD
Naproxen—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	7.73e-05	0.000695	CcSEcCtD
Naproxen—Vascular purpura—Prednisone—chronic obstructive pulmonary disease	7.69e-05	0.000692	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	7.67e-05	0.00069	CcSEcCtD
Naproxen—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	7.66e-05	0.000689	CcSEcCtD
Naproxen—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	7.66e-05	0.000689	CcSEcCtD
Naproxen—Ketoprofen—ALB—chronic obstructive pulmonary disease	7.65e-05	0.0262	CrCbGaD
Naproxen—Somnolence—Formoterol—chronic obstructive pulmonary disease	7.64e-05	0.000687	CcSEcCtD
Naproxen—Somnolence—Arformoterol—chronic obstructive pulmonary disease	7.64e-05	0.000687	CcSEcCtD
Naproxen—Insomnia—Montelukast—chronic obstructive pulmonary disease	7.61e-05	0.000685	CcSEcCtD
Naproxen—Cardiac failure congestive—Prednisone—chronic obstructive pulmonary disease	7.59e-05	0.000683	CcSEcCtD
Naproxen—Hypotension—Salbutamol—chronic obstructive pulmonary disease	7.58e-05	0.000682	CcSEcCtD
Naproxen—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	7.57e-05	0.000681	CcSEcCtD
Naproxen—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	7.57e-05	0.000681	CcSEcCtD
Naproxen—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	7.56e-05	0.00068	CcSEcCtD
Naproxen—Ibuprofen—ALB—chronic obstructive pulmonary disease	7.54e-05	0.0258	CrCbGaD
Naproxen—Pruritus—Tiotropium—chronic obstructive pulmonary disease	7.53e-05	0.000678	CcSEcCtD
Naproxen—Somnolence—Montelukast—chronic obstructive pulmonary disease	7.48e-05	0.000673	CcSEcCtD
Naproxen—Dizziness—Aminophylline—chronic obstructive pulmonary disease	7.47e-05	0.000672	CcSEcCtD
Naproxen—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	7.42e-05	0.000668	CcSEcCtD
Naproxen—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	7.42e-05	0.000668	CcSEcCtD
Naproxen—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	7.41e-05	0.000667	CcSEcCtD
Naproxen—Fatigue—Arformoterol—chronic obstructive pulmonary disease	7.41e-05	0.000667	CcSEcCtD
Naproxen—Fatigue—Formoterol—chronic obstructive pulmonary disease	7.41e-05	0.000667	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	7.39e-05	0.000665	CcSEcCtD
Naproxen—Constipation—Formoterol—chronic obstructive pulmonary disease	7.35e-05	0.000661	CcSEcCtD
Naproxen—Pain—Arformoterol—chronic obstructive pulmonary disease	7.35e-05	0.000661	CcSEcCtD
Naproxen—Constipation—Arformoterol—chronic obstructive pulmonary disease	7.35e-05	0.000661	CcSEcCtD
Naproxen—Pain—Formoterol—chronic obstructive pulmonary disease	7.35e-05	0.000661	CcSEcCtD
Naproxen—Insomnia—Salbutamol—chronic obstructive pulmonary disease	7.34e-05	0.00066	CcSEcCtD
Naproxen—Amnesia—Prednisone—chronic obstructive pulmonary disease	7.32e-05	0.000659	CcSEcCtD
Naproxen—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	7.29e-05	0.000656	CcSEcCtD
Naproxen—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	7.27e-05	0.000654	CcSEcCtD
Naproxen—Fatigue—Montelukast—chronic obstructive pulmonary disease	7.26e-05	0.000653	CcSEcCtD
Naproxen—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	7.24e-05	0.000651	CcSEcCtD
Naproxen—Somnolence—Salbutamol—chronic obstructive pulmonary disease	7.21e-05	0.000649	CcSEcCtD
Naproxen—Pain—Montelukast—chronic obstructive pulmonary disease	7.2e-05	0.000648	CcSEcCtD
Naproxen—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	7.19e-05	0.000647	CcSEcCtD
Naproxen—Vomiting—Aminophylline—chronic obstructive pulmonary disease	7.18e-05	0.000646	CcSEcCtD
Naproxen—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	7.15e-05	0.000644	CcSEcCtD
Naproxen—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	7.15e-05	0.000644	CcSEcCtD
Naproxen—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	7.14e-05	0.000643	CcSEcCtD
Naproxen—Purpura—Prednisone—chronic obstructive pulmonary disease	7.14e-05	0.000642	CcSEcCtD
Naproxen—Rash—Aminophylline—chronic obstructive pulmonary disease	7.12e-05	0.000641	CcSEcCtD
Naproxen—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	7.11e-05	0.00064	CcSEcCtD
Naproxen—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	7.09e-05	0.000638	CcSEcCtD
Naproxen—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	7.08e-05	0.000637	CcSEcCtD
Naproxen—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	7.08e-05	0.000637	CcSEcCtD
Naproxen—Headache—Aminophylline—chronic obstructive pulmonary disease	7.07e-05	0.000636	CcSEcCtD
Naproxen—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	7.05e-05	0.000635	CcSEcCtD
Naproxen—Cardiac failure—Prednisone—chronic obstructive pulmonary disease	7.05e-05	0.000634	CcSEcCtD
Naproxen—Dizziness—Tiotropium—chronic obstructive pulmonary disease	7.04e-05	0.000634	CcSEcCtD
Naproxen—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	7.03e-05	0.000632	CcSEcCtD
Naproxen—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	7.03e-05	0.000632	CcSEcCtD
Naproxen—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	7.01e-05	0.00063	CcSEcCtD
Naproxen—Fatigue—Salbutamol—chronic obstructive pulmonary disease	7e-05	0.000629	CcSEcCtD
Naproxen—Pain—Salbutamol—chronic obstructive pulmonary disease	6.94e-05	0.000624	CcSEcCtD
Naproxen—Constipation—Salbutamol—chronic obstructive pulmonary disease	6.94e-05	0.000624	CcSEcCtD
Naproxen—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	6.88e-05	0.000619	CcSEcCtD
Naproxen—Osteoarthritis—Prednisone—chronic obstructive pulmonary disease	6.88e-05	0.000619	CcSEcCtD
Naproxen—Gastrointestinal haemorrhage—Prednisone—chronic obstructive pulmonary disease	6.88e-05	0.000619	CcSEcCtD
Naproxen—Urticaria—Arformoterol—chronic obstructive pulmonary disease	6.83e-05	0.000614	CcSEcCtD
Naproxen—Urticaria—Formoterol—chronic obstructive pulmonary disease	6.83e-05	0.000614	CcSEcCtD
Naproxen—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	6.79e-05	0.000611	CcSEcCtD
Naproxen—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	6.79e-05	0.000611	CcSEcCtD
Naproxen—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	6.79e-05	0.000611	CcSEcCtD
Naproxen—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	6.79e-05	0.000611	CcSEcCtD
Naproxen—Affect lability—Prednisone—chronic obstructive pulmonary disease	6.77e-05	0.000609	CcSEcCtD
Naproxen—Vomiting—Tiotropium—chronic obstructive pulmonary disease	6.77e-05	0.000609	CcSEcCtD
Naproxen—Rash—Tiotropium—chronic obstructive pulmonary disease	6.71e-05	0.000604	CcSEcCtD
Naproxen—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	6.71e-05	0.000604	CcSEcCtD
Naproxen—Nausea—Aminophylline—chronic obstructive pulmonary disease	6.71e-05	0.000603	CcSEcCtD
Naproxen—Urticaria—Montelukast—chronic obstructive pulmonary disease	6.69e-05	0.000602	CcSEcCtD
Naproxen—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	6.69e-05	0.000602	CcSEcCtD
Naproxen—Headache—Tiotropium—chronic obstructive pulmonary disease	6.67e-05	0.0006	CcSEcCtD
Naproxen—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	6.65e-05	0.000599	CcSEcCtD
Naproxen—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	6.65e-05	0.000599	CcSEcCtD
Naproxen—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	6.64e-05	0.000597	CcSEcCtD
Naproxen—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	6.58e-05	0.000592	CcSEcCtD
Naproxen—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	6.55e-05	0.000589	CcSEcCtD
Naproxen—Mood swings—Prednisone—chronic obstructive pulmonary disease	6.52e-05	0.000587	CcSEcCtD
Naproxen—Urticaria—Salbutamol—chronic obstructive pulmonary disease	6.45e-05	0.00058	CcSEcCtD
Naproxen—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	6.42e-05	0.000577	CcSEcCtD
Naproxen—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	6.42e-05	0.000577	CcSEcCtD
Naproxen—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	6.33e-05	0.00057	CcSEcCtD
Naproxen—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	6.33e-05	0.00057	CcSEcCtD
Naproxen—Nausea—Tiotropium—chronic obstructive pulmonary disease	6.33e-05	0.000569	CcSEcCtD
Naproxen—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	6.31e-05	0.000568	CcSEcCtD
Naproxen—Dry skin—Prednisone—chronic obstructive pulmonary disease	6.31e-05	0.000568	CcSEcCtD
Naproxen—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	6.26e-05	0.000563	CcSEcCtD
Naproxen—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	6.2e-05	0.000558	CcSEcCtD
Naproxen—Asthenia—Formoterol—chronic obstructive pulmonary disease	6.17e-05	0.000555	CcSEcCtD
Naproxen—Asthenia—Arformoterol—chronic obstructive pulmonary disease	6.17e-05	0.000555	CcSEcCtD
Naproxen—Pruritus—Arformoterol—chronic obstructive pulmonary disease	6.08e-05	0.000547	CcSEcCtD
Naproxen—Pruritus—Formoterol—chronic obstructive pulmonary disease	6.08e-05	0.000547	CcSEcCtD
Naproxen—Muscular weakness—Prednisone—chronic obstructive pulmonary disease	6.07e-05	0.000546	CcSEcCtD
Naproxen—Asthenia—Montelukast—chronic obstructive pulmonary disease	6.04e-05	0.000543	CcSEcCtD
Naproxen—Abdominal distension—Prednisone—chronic obstructive pulmonary disease	5.99e-05	0.000539	CcSEcCtD
Naproxen—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	5.98e-05	0.000538	CcSEcCtD
Naproxen—Pruritus—Montelukast—chronic obstructive pulmonary disease	5.96e-05	0.000536	CcSEcCtD
Naproxen—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	5.88e-05	0.000529	CcSEcCtD
Naproxen—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	5.88e-05	0.000529	CcSEcCtD
Naproxen—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	5.85e-05	0.000527	CcSEcCtD
Naproxen—Pancreatitis—Prednisone—chronic obstructive pulmonary disease	5.83e-05	0.000525	CcSEcCtD
Naproxen—Asthenia—Salbutamol—chronic obstructive pulmonary disease	5.82e-05	0.000524	CcSEcCtD
Naproxen—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	5.76e-05	0.000518	CcSEcCtD
Naproxen—Pruritus—Salbutamol—chronic obstructive pulmonary disease	5.74e-05	0.000517	CcSEcCtD
Naproxen—Erythema—Prednisolone—chronic obstructive pulmonary disease	5.7e-05	0.000513	CcSEcCtD
Naproxen—Dizziness—Formoterol—chronic obstructive pulmonary disease	5.68e-05	0.000511	CcSEcCtD
Naproxen—Dizziness—Arformoterol—chronic obstructive pulmonary disease	5.68e-05	0.000511	CcSEcCtD
Naproxen—Dizziness—Montelukast—chronic obstructive pulmonary disease	5.57e-05	0.000501	CcSEcCtD
Naproxen—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	5.55e-05	0.0005	CcSEcCtD
Naproxen—Vomiting—Arformoterol—chronic obstructive pulmonary disease	5.46e-05	0.000492	CcSEcCtD
Naproxen—Vomiting—Formoterol—chronic obstructive pulmonary disease	5.46e-05	0.000492	CcSEcCtD
Naproxen—Rash—Formoterol—chronic obstructive pulmonary disease	5.42e-05	0.000488	CcSEcCtD
Naproxen—Rash—Arformoterol—chronic obstructive pulmonary disease	5.42e-05	0.000488	CcSEcCtD
Naproxen—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	5.41e-05	0.000487	CcSEcCtD
Naproxen—Dermatitis—Formoterol—chronic obstructive pulmonary disease	5.41e-05	0.000487	CcSEcCtD
Naproxen—Headache—Formoterol—chronic obstructive pulmonary disease	5.38e-05	0.000484	CcSEcCtD
Naproxen—Headache—Arformoterol—chronic obstructive pulmonary disease	5.38e-05	0.000484	CcSEcCtD
Naproxen—Weight decreased—Prednisone—chronic obstructive pulmonary disease	5.38e-05	0.000484	CcSEcCtD
Naproxen—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	5.37e-05	0.000484	CcSEcCtD
Naproxen—Dizziness—Salbutamol—chronic obstructive pulmonary disease	5.37e-05	0.000483	CcSEcCtD
Naproxen—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	5.37e-05	0.000483	CcSEcCtD
Naproxen—Vomiting—Montelukast—chronic obstructive pulmonary disease	5.35e-05	0.000482	CcSEcCtD
Naproxen—Rash—Montelukast—chronic obstructive pulmonary disease	5.31e-05	0.000478	CcSEcCtD
Naproxen—Dermatitis—Montelukast—chronic obstructive pulmonary disease	5.3e-05	0.000477	CcSEcCtD
Naproxen—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	5.29e-05	0.000476	CcSEcCtD
Naproxen—Depression—Prednisone—chronic obstructive pulmonary disease	5.29e-05	0.000476	CcSEcCtD
Naproxen—Headache—Montelukast—chronic obstructive pulmonary disease	5.27e-05	0.000474	CcSEcCtD
Naproxen—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	5.23e-05	0.00047	CcSEcCtD
Naproxen—Angioedema—Prednisolone—chronic obstructive pulmonary disease	5.21e-05	0.000469	CcSEcCtD
Naproxen—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	5.2e-05	0.000468	CcSEcCtD
Naproxen—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	5.2e-05	0.000468	CcSEcCtD
Naproxen—Vomiting—Salbutamol—chronic obstructive pulmonary disease	5.16e-05	0.000464	CcSEcCtD
Naproxen—Malaise—Prednisolone—chronic obstructive pulmonary disease	5.14e-05	0.000463	CcSEcCtD
Naproxen—Vertigo—Prednisolone—chronic obstructive pulmonary disease	5.12e-05	0.000461	CcSEcCtD
Naproxen—Rash—Salbutamol—chronic obstructive pulmonary disease	5.12e-05	0.00046	CcSEcCtD
Naproxen—Syncope—Prednisolone—chronic obstructive pulmonary disease	5.11e-05	0.00046	CcSEcCtD
Naproxen—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	5.11e-05	0.00046	CcSEcCtD
Naproxen—Nausea—Formoterol—chronic obstructive pulmonary disease	5.11e-05	0.000459	CcSEcCtD
Naproxen—Nausea—Arformoterol—chronic obstructive pulmonary disease	5.11e-05	0.000459	CcSEcCtD
Naproxen—Headache—Salbutamol—chronic obstructive pulmonary disease	5.08e-05	0.000457	CcSEcCtD
Naproxen—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	5.01e-05	0.000451	CcSEcCtD
Naproxen—Nausea—Montelukast—chronic obstructive pulmonary disease	5e-05	0.00045	CcSEcCtD
Naproxen—Convulsion—Prednisolone—chronic obstructive pulmonary disease	4.94e-05	0.000445	CcSEcCtD
Naproxen—Hypertension—Prednisolone—chronic obstructive pulmonary disease	4.92e-05	0.000443	CcSEcCtD
Naproxen—AKR1C3—bronchus—chronic obstructive pulmonary disease	4.85e-05	0.1	CbGeAlD
Naproxen—Nausea—Salbutamol—chronic obstructive pulmonary disease	4.82e-05	0.000434	CcSEcCtD
Naproxen—Discomfort—Prednisolone—chronic obstructive pulmonary disease	4.8e-05	0.000432	CcSEcCtD
Naproxen—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	4.79e-05	0.00043	CcSEcCtD
Naproxen—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	4.76e-05	0.000428	CcSEcCtD
Naproxen—AKR1C3—smooth muscle tissue—chronic obstructive pulmonary disease	4.75e-05	0.0978	CbGeAlD
Naproxen—Hallucination—Prednisone—chronic obstructive pulmonary disease	4.74e-05	0.000426	CcSEcCtD
Naproxen—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	4.68e-05	0.000421	CcSEcCtD
Naproxen—Oedema—Prednisolone—chronic obstructive pulmonary disease	4.65e-05	0.000419	CcSEcCtD
Naproxen—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	4.65e-05	0.000419	CcSEcCtD
Naproxen—Shock—Prednisolone—chronic obstructive pulmonary disease	4.58e-05	0.000412	CcSEcCtD
Naproxen—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	4.54e-05	0.000409	CcSEcCtD
Naproxen—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	4.5e-05	0.000405	CcSEcCtD
Naproxen—Eye disorder—Prednisone—chronic obstructive pulmonary disease	4.45e-05	0.0004	CcSEcCtD
Naproxen—AKR1C3—trachea—chronic obstructive pulmonary disease	4.36e-05	0.0898	CbGeAlD
Naproxen—Angiopathy—Prednisone—chronic obstructive pulmonary disease	4.32e-05	0.000389	CcSEcCtD
Naproxen—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	4.3e-05	0.000387	CcSEcCtD
Naproxen—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	4.25e-05	0.000383	CcSEcCtD
Naproxen—Insomnia—Prednisolone—chronic obstructive pulmonary disease	4.21e-05	0.000379	CcSEcCtD
Naproxen—Alopecia—Prednisone—chronic obstructive pulmonary disease	4.21e-05	0.000378	CcSEcCtD
Naproxen—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	4.18e-05	0.000376	CcSEcCtD
Naproxen—Mental disorder—Prednisone—chronic obstructive pulmonary disease	4.17e-05	0.000375	CcSEcCtD
Naproxen—Erythema—Prednisone—chronic obstructive pulmonary disease	4.14e-05	0.000373	CcSEcCtD
Naproxen—Malnutrition—Prednisone—chronic obstructive pulmonary disease	4.14e-05	0.000373	CcSEcCtD
Naproxen—Pain—Prednisolone—chronic obstructive pulmonary disease	3.98e-05	0.000358	CcSEcCtD
Naproxen—Vision blurred—Prednisone—chronic obstructive pulmonary disease	3.91e-05	0.000351	CcSEcCtD
Naproxen—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	3.85e-05	0.000346	CcSEcCtD
Naproxen—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	3.84e-05	0.000345	CcSEcCtD
Naproxen—Anaemia—Prednisone—chronic obstructive pulmonary disease	3.83e-05	0.000345	CcSEcCtD
Naproxen—Angioedema—Prednisone—chronic obstructive pulmonary disease	3.79e-05	0.000341	CcSEcCtD
Naproxen—Malaise—Prednisone—chronic obstructive pulmonary disease	3.74e-05	0.000336	CcSEcCtD
Naproxen—Vertigo—Prednisone—chronic obstructive pulmonary disease	3.72e-05	0.000335	CcSEcCtD
Naproxen—Syncope—Prednisone—chronic obstructive pulmonary disease	3.72e-05	0.000334	CcSEcCtD
Naproxen—Urticaria—Prednisolone—chronic obstructive pulmonary disease	3.7e-05	0.000333	CcSEcCtD
Naproxen—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	3.64e-05	0.000328	CcSEcCtD
Naproxen—Convulsion—Prednisone—chronic obstructive pulmonary disease	3.59e-05	0.000323	CcSEcCtD
Naproxen—Hypertension—Prednisone—chronic obstructive pulmonary disease	3.58e-05	0.000322	CcSEcCtD
Naproxen—Myalgia—Prednisone—chronic obstructive pulmonary disease	3.53e-05	0.000317	CcSEcCtD
Naproxen—Arthralgia—Prednisone—chronic obstructive pulmonary disease	3.53e-05	0.000317	CcSEcCtD
Naproxen—Anxiety—Prednisone—chronic obstructive pulmonary disease	3.52e-05	0.000316	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	3.5e-05	0.000315	CcSEcCtD
Naproxen—Discomfort—Prednisone—chronic obstructive pulmonary disease	3.49e-05	0.000314	CcSEcCtD
Naproxen—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	3.43e-05	0.000309	CcSEcCtD
Naproxen—Oedema—Prednisone—chronic obstructive pulmonary disease	3.38e-05	0.000304	CcSEcCtD
Naproxen—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	3.38e-05	0.000304	CcSEcCtD
Naproxen—Infection—Prednisone—chronic obstructive pulmonary disease	3.36e-05	0.000302	CcSEcCtD
Naproxen—Shock—Prednisone—chronic obstructive pulmonary disease	3.33e-05	0.000299	CcSEcCtD
Naproxen—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	3.32e-05	0.000298	CcSEcCtD
Naproxen—Tachycardia—Prednisone—chronic obstructive pulmonary disease	3.3e-05	0.000297	CcSEcCtD
Naproxen—Skin disorder—Prednisone—chronic obstructive pulmonary disease	3.29e-05	0.000296	CcSEcCtD
Naproxen—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	3.27e-05	0.000294	CcSEcCtD
Naproxen—Anorexia—Prednisone—chronic obstructive pulmonary disease	3.22e-05	0.00029	CcSEcCtD
Naproxen—AKR1C3—lung—chronic obstructive pulmonary disease	3.13e-05	0.0645	CbGeAlD
Naproxen—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	3.08e-05	0.000277	CcSEcCtD
Naproxen—Dizziness—Prednisolone—chronic obstructive pulmonary disease	3.08e-05	0.000277	CcSEcCtD
Naproxen—Insomnia—Prednisone—chronic obstructive pulmonary disease	3.06e-05	0.000275	CcSEcCtD
Naproxen—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	3.04e-05	0.000273	CcSEcCtD
Naproxen—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	2.98e-05	0.000268	CcSEcCtD
Naproxen—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	2.94e-05	0.000265	CcSEcCtD
Naproxen—Rash—Prednisolone—chronic obstructive pulmonary disease	2.93e-05	0.000264	CcSEcCtD
Naproxen—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	2.93e-05	0.000264	CcSEcCtD
Naproxen—Fatigue—Prednisone—chronic obstructive pulmonary disease	2.92e-05	0.000262	CcSEcCtD
Naproxen—Headache—Prednisolone—chronic obstructive pulmonary disease	2.92e-05	0.000262	CcSEcCtD
Naproxen—Constipation—Prednisone—chronic obstructive pulmonary disease	2.89e-05	0.00026	CcSEcCtD
Naproxen—CYP2C8—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2.87e-05	0.000668	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—GC—chronic obstructive pulmonary disease	2.86e-05	0.000667	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.85e-05	0.000665	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.82e-05	0.000656	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—CXCL8—chronic obstructive pulmonary disease	2.79e-05	0.000649	CbGpPWpGaD
Naproxen—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	2.79e-05	0.000251	CcSEcCtD
Naproxen—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	2.77e-05	0.000249	CcSEcCtD
Naproxen—Nausea—Prednisolone—chronic obstructive pulmonary disease	2.76e-05	0.000249	CcSEcCtD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	2.76e-05	0.000642	CbGpPWpGaD
Naproxen—ALB—Selenium Micronutrient Network—IL1B—chronic obstructive pulmonary disease	2.74e-05	0.000637	CbGpPWpGaD
Naproxen—AKR1C3—Disease—KL—chronic obstructive pulmonary disease	2.73e-05	0.000637	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—chronic obstructive pulmonary disease	2.72e-05	0.000634	CbGpPWpGaD
Naproxen—SLC22A6—SLC-mediated transmembrane transport—ALB—chronic obstructive pulmonary disease	2.72e-05	0.000633	CbGpPWpGaD
Naproxen—CYP2C9—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	2.72e-05	0.000633	CbGpPWpGaD
Naproxen—UGT1A1—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	2.71e-05	0.000631	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	2.7e-05	0.000629	CbGpPWpGaD
Naproxen—Urticaria—Prednisone—chronic obstructive pulmonary disease	2.69e-05	0.000242	CcSEcCtD
Naproxen—CYP2C9—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	2.68e-05	0.000624	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—IL1B—chronic obstructive pulmonary disease	2.67e-05	0.000623	CbGpPWpGaD
Naproxen—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	2.67e-05	0.000241	CcSEcCtD
Naproxen—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	2.67e-05	0.000241	CcSEcCtD
Naproxen—UGT1A1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.66e-05	0.00062	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—CTGF—chronic obstructive pulmonary disease	2.64e-05	0.000616	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	2.58e-05	0.000602	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—MMP9—chronic obstructive pulmonary disease	2.52e-05	0.000587	CbGpPWpGaD
Naproxen—ALB—Platelet degranulation—VEGFA—chronic obstructive pulmonary disease	2.5e-05	0.000582	CbGpPWpGaD
Naproxen—ALB—Folate Metabolism—TNF—chronic obstructive pulmonary disease	2.5e-05	0.000582	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—chronic obstructive pulmonary disease	2.5e-05	0.000582	CbGpPWpGaD
Naproxen—CYP2C9—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	2.5e-05	0.000582	CbGpPWpGaD
Naproxen—PTGS1—Selenium Micronutrient Network—IL6—chronic obstructive pulmonary disease	2.49e-05	0.000581	CbGpPWpGaD
Naproxen—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	2.49e-05	0.000224	CcSEcCtD
Naproxen—ALB—Vitamin B12 Metabolism—IL6—chronic obstructive pulmonary disease	2.48e-05	0.000577	CbGpPWpGaD
Naproxen—CYP2C9—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	2.46e-05	0.000574	CbGpPWpGaD
Naproxen—PTGS2—Selenium Micronutrient Network—TNF—chronic obstructive pulmonary disease	2.45e-05	0.000571	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—chronic obstructive pulmonary disease	2.45e-05	0.000571	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—chronic obstructive pulmonary disease	2.45e-05	0.000571	CbGpPWpGaD
Naproxen—SLCO1A2—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	2.45e-05	0.00057	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.44e-05	0.000567	CbGpPWpGaD
Naproxen—Asthenia—Prednisone—chronic obstructive pulmonary disease	2.43e-05	0.000218	CcSEcCtD
Naproxen—CYP1A2—respiratory system—chronic obstructive pulmonary disease	2.41e-05	0.0496	CbGeAlD
Naproxen—PTGS1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.4e-05	0.000559	CbGpPWpGaD
Naproxen—Pruritus—Prednisone—chronic obstructive pulmonary disease	2.39e-05	0.000215	CcSEcCtD
Naproxen—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—chronic obstructive pulmonary disease	2.38e-05	0.000555	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	2.38e-05	0.000554	CbGpPWpGaD
Naproxen—CYP2C9—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	2.37e-05	0.000551	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	2.36e-05	0.000549	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—APIP—chronic obstructive pulmonary disease	2.34e-05	0.000545	CbGpPWpGaD
Naproxen—CYP2C9—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2.34e-05	0.000544	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—GC—chronic obstructive pulmonary disease	2.33e-05	0.000544	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—TNF—chronic obstructive pulmonary disease	2.33e-05	0.000543	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—chronic obstructive pulmonary disease	2.33e-05	0.000543	CbGpPWpGaD
Naproxen—ALB—Metabolism—APIP—chronic obstructive pulmonary disease	2.33e-05	0.000542	CbGpPWpGaD
Naproxen—CYP1A2—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	2.32e-05	0.000541	CbGpPWpGaD
Naproxen—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	2.31e-05	0.000208	CcSEcCtD
Naproxen—SLC22A6—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	2.3e-05	0.000536	CbGpPWpGaD
Naproxen—ALB—Platelet degranulation—TGFB1—chronic obstructive pulmonary disease	2.29e-05	0.000534	CbGpPWpGaD
Naproxen—CYP1A2—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	2.29e-05	0.000533	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	2.27e-05	0.000529	CbGpPWpGaD
Naproxen—Dizziness—Prednisone—chronic obstructive pulmonary disease	2.24e-05	0.000201	CcSEcCtD
Naproxen—ALB—Folate Metabolism—TP53—chronic obstructive pulmonary disease	2.2e-05	0.000513	CbGpPWpGaD
Naproxen—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—chronic obstructive pulmonary disease	2.19e-05	0.000509	CbGpPWpGaD
Naproxen—ALB—Hemostasis—SERPINA1—chronic obstructive pulmonary disease	2.18e-05	0.000509	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.17e-05	0.000506	CbGpPWpGaD
Naproxen—Vomiting—Prednisone—chronic obstructive pulmonary disease	2.15e-05	0.000193	CcSEcCtD
Naproxen—CYP1A2—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	2.13e-05	0.000497	CbGpPWpGaD
Naproxen—Rash—Prednisone—chronic obstructive pulmonary disease	2.13e-05	0.000192	CcSEcCtD
Naproxen—Dermatitis—Prednisone—chronic obstructive pulmonary disease	2.13e-05	0.000192	CcSEcCtD
Naproxen—Headache—Prednisone—chronic obstructive pulmonary disease	2.12e-05	0.000191	CcSEcCtD
Naproxen—CYP1A2—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	2.1e-05	0.00049	CbGpPWpGaD
Naproxen—PTGS1—respiratory system—chronic obstructive pulmonary disease	2.09e-05	0.043	CbGeAlD
Naproxen—PTGS2—Spinal Cord Injury—TGFB1—chronic obstructive pulmonary disease	2.08e-05	0.000484	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	2.06e-05	0.00048	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	2.05e-05	0.000478	CbGpPWpGaD
Naproxen—AKR1C3—Disease—ERBB3—chronic obstructive pulmonary disease	2.05e-05	0.000477	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—EGFR—chronic obstructive pulmonary disease	2.04e-05	0.000475	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.03e-05	0.000473	CbGpPWpGaD
Naproxen—CYP1A2—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	2.02e-05	0.000471	CbGpPWpGaD
Naproxen—ALB—Folate Metabolism—IL6—chronic obstructive pulmonary disease	2.02e-05	0.00047	CbGpPWpGaD
Naproxen—Nausea—Prednisone—chronic obstructive pulmonary disease	2.01e-05	0.000181	CcSEcCtD
Naproxen—AKR1C3—Metabolism—HMOX1—chronic obstructive pulmonary disease	2e-05	0.000467	CbGpPWpGaD
Naproxen—CYP1A2—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2e-05	0.000465	CbGpPWpGaD
Naproxen—PTGS2—respiratory system—chronic obstructive pulmonary disease	1.99e-05	0.0411	CbGeAlD
Naproxen—ALB—Selenium Micronutrient Network—TNF—chronic obstructive pulmonary disease	1.99e-05	0.000462	CbGpPWpGaD
Naproxen—PTGS2—Selenium Micronutrient Network—IL6—chronic obstructive pulmonary disease	1.98e-05	0.000461	CbGpPWpGaD
Naproxen—SLCO1A2—lung—chronic obstructive pulmonary disease	1.95e-05	0.0403	CbGeAlD
Naproxen—PTGS2—Spinal Cord Injury—TNF—chronic obstructive pulmonary disease	1.94e-05	0.000452	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.93e-05	0.000448	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.91e-05	0.000446	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.91e-05	0.000444	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—APIP—chronic obstructive pulmonary disease	1.9e-05	0.000444	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—GCLC—chronic obstructive pulmonary disease	1.9e-05	0.000443	CbGpPWpGaD
Naproxen—ALB—Hemostasis—TGFB2—chronic obstructive pulmonary disease	1.89e-05	0.000441	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	1.89e-05	0.00044	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.87e-05	0.000435	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—GC—chronic obstructive pulmonary disease	1.85e-05	0.000432	CbGpPWpGaD
Naproxen—PTGS1—connective tissue—chronic obstructive pulmonary disease	1.84e-05	0.0378	CbGeAlD
Naproxen—AKR1C3—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.77e-05	0.000412	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.77e-05	0.000411	CbGpPWpGaD
Naproxen—PTGS2—connective tissue—chronic obstructive pulmonary disease	1.75e-05	0.0362	CbGeAlD
Naproxen—UGT2B7—Metabolism—CTGF—chronic obstructive pulmonary disease	1.74e-05	0.000404	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.73e-05	0.000403	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.72e-05	0.000401	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—TP53—chronic obstructive pulmonary disease	1.71e-05	0.000398	CbGpPWpGaD
Naproxen—AKR1C3—Disease—NOS2—chronic obstructive pulmonary disease	1.71e-05	0.000398	CbGpPWpGaD
Naproxen—ALB—Hemostasis—HDAC2—chronic obstructive pulmonary disease	1.7e-05	0.000396	CbGpPWpGaD
Naproxen—PTGS1—smooth muscle tissue—chronic obstructive pulmonary disease	1.68e-05	0.0346	CbGeAlD
Naproxen—SLCO1A2—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.68e-05	0.00039	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.67e-05	0.000389	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.66e-05	0.000386	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—GCLC—chronic obstructive pulmonary disease	1.66e-05	0.000386	CbGpPWpGaD
Naproxen—PTGS2—bronchus—chronic obstructive pulmonary disease	1.64e-05	0.0338	CbGeAlD
Naproxen—CYP1A2—Metabolism—APIP—chronic obstructive pulmonary disease	1.63e-05	0.000379	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—SERPINE1—chronic obstructive pulmonary disease	1.61e-05	0.000375	CbGpPWpGaD
Naproxen—PTGS2—smooth muscle tissue—chronic obstructive pulmonary disease	1.61e-05	0.0331	CbGeAlD
Naproxen—ALB—Selenium Micronutrient Network—IL6—chronic obstructive pulmonary disease	1.6e-05	0.000373	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.6e-05	0.000373	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.58e-05	0.000368	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—IL6—chronic obstructive pulmonary disease	1.57e-05	0.000365	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.56e-05	0.000364	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.55e-05	0.000361	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—GCLC—chronic obstructive pulmonary disease	1.55e-05	0.00036	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.55e-05	0.00036	CbGpPWpGaD
Naproxen—ALB—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.54e-05	0.000359	CbGpPWpGaD
Naproxen—PTGS1—trachea—chronic obstructive pulmonary disease	1.54e-05	0.0318	CbGeAlD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	1.54e-05	0.000359	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	1.54e-05	0.000358	CbGpPWpGaD
Naproxen—ALB—Hemostasis—PLAUR—chronic obstructive pulmonary disease	1.53e-05	0.000357	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	1.53e-05	0.000356	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—CTGF—chronic obstructive pulmonary disease	1.51e-05	0.000352	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GC—chronic obstructive pulmonary disease	1.51e-05	0.000351	CbGpPWpGaD
Naproxen—ALB—Metabolism—GC—chronic obstructive pulmonary disease	1.5e-05	0.000349	CbGpPWpGaD
Naproxen—PTGS2—trachea—chronic obstructive pulmonary disease	1.47e-05	0.0304	CbGeAlD
Naproxen—SLCO1A2—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	1.47e-05	0.000342	CbGpPWpGaD
Naproxen—AKR1C3—Disease—SERPINE1—chronic obstructive pulmonary disease	1.44e-05	0.000335	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.44e-05	0.000334	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	1.41e-05	0.000329	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—CTGF—chronic obstructive pulmonary disease	1.41e-05	0.000329	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.4e-05	0.000327	CbGpPWpGaD
Naproxen—ALB—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.39e-05	0.000325	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.39e-05	0.000325	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	1.39e-05	0.000323	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.38e-05	0.000322	CbGpPWpGaD
Naproxen—SLC22A6—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	1.38e-05	0.000322	CbGpPWpGaD
Naproxen—AKR1C3—Disease—NOS3—chronic obstructive pulmonary disease	1.37e-05	0.00032	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.37e-05	0.00032	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.36e-05	0.000316	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.33e-05	0.000311	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	1.32e-05	0.000307	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.32e-05	0.000307	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.3e-05	0.000303	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.28e-05	0.000299	CbGpPWpGaD
Naproxen—CYP1A2—lung—chronic obstructive pulmonary disease	1.28e-05	0.0263	CbGeAlD
Naproxen—PTGS1—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.28e-05	0.000297	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.26e-05	0.000294	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—GCLC—chronic obstructive pulmonary disease	1.26e-05	0.000294	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	1.25e-05	0.000291	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GC—chronic obstructive pulmonary disease	1.23e-05	0.000286	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.23e-05	0.000286	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—ALB—chronic obstructive pulmonary disease	1.2e-05	0.00028	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	1.2e-05	0.000278	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.18e-05	0.000274	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	1.16e-05	0.000271	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.16e-05	0.000271	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.16e-05	0.000271	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.16e-05	0.00027	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—NOS3—chronic obstructive pulmonary disease	1.15e-05	0.000268	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—CTGF—chronic obstructive pulmonary disease	1.15e-05	0.000268	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.15e-05	0.000267	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.14e-05	0.000266	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.12e-05	0.00026	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.11e-05	0.000259	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—VEGFA—chronic obstructive pulmonary disease	1.11e-05	0.000258	CbGpPWpGaD
Naproxen—PTGS1—lung—chronic obstructive pulmonary disease	1.11e-05	0.0228	CbGeAlD
Naproxen—ALB—Hemostasis—MMP1—chronic obstructive pulmonary disease	1.09e-05	0.000255	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.08e-05	0.000253	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.08e-05	0.000251	CbGpPWpGaD
Naproxen—ALB—Hemostasis—PLAU—chronic obstructive pulmonary disease	1.07e-05	0.00025	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.07e-05	0.000249	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.07e-05	0.000249	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.06e-05	0.000247	CbGpPWpGaD
Naproxen—PTGS2—lung—chronic obstructive pulmonary disease	1.06e-05	0.0218	CbGeAlD
Naproxen—CYP1A2—Metabolism—GC—chronic obstructive pulmonary disease	1.05e-05	0.000244	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—TGFB1—chronic obstructive pulmonary disease	1.02e-05	0.000237	CbGpPWpGaD
Naproxen—PTGS2—Disease—HDAC2—chronic obstructive pulmonary disease	1.02e-05	0.000237	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.01e-05	0.000236	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.01e-05	0.000236	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.01e-05	0.000235	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—GCLC—chronic obstructive pulmonary disease	1e-05	0.000233	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—GSTM1—chronic obstructive pulmonary disease	9.97e-06	0.000232	CbGpPWpGaD
Naproxen—ALB—Hemostasis—NOS2—chronic obstructive pulmonary disease	9.87e-06	0.00023	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	9.75e-06	0.000227	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	9.62e-06	0.000224	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	9.45e-06	0.00022	CbGpPWpGaD
Naproxen—PTGS2—Disease—KL—chronic obstructive pulmonary disease	9.45e-06	0.00022	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	9.33e-06	0.000217	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CTGF—chronic obstructive pulmonary disease	9.13e-06	0.000213	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	9.09e-06	0.000212	CbGpPWpGaD
Naproxen—AKR1C3—Disease—TGFB1—chronic obstructive pulmonary disease	9.08e-06	0.000212	CbGpPWpGaD
Naproxen—AKR1C3—Disease—EGFR—chronic obstructive pulmonary disease	8.91e-06	0.000207	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—GSTP1—chronic obstructive pulmonary disease	8.84e-06	0.000206	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—HMOX1—chronic obstructive pulmonary disease	8.72e-06	0.000203	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	8.53e-06	0.000199	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CYP1A2—chronic obstructive pulmonary disease	8.41e-06	0.000196	CbGpPWpGaD
Naproxen—ALB—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	8.31e-06	0.000194	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GSTT1—chronic obstructive pulmonary disease	8.24e-06	0.000192	CbGpPWpGaD
Naproxen—ALB—Metabolism—GSTT1—chronic obstructive pulmonary disease	8.19e-06	0.000191	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GCLC—chronic obstructive pulmonary disease	8.14e-06	0.00019	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—GSTM1—chronic obstructive pulmonary disease	8.12e-06	0.000189	CbGpPWpGaD
Naproxen—ALB—Metabolism—GCLC—chronic obstructive pulmonary disease	8.1e-06	0.000189	CbGpPWpGaD
Naproxen—ALB—Hemostasis—NOS3—chronic obstructive pulmonary disease	7.93e-06	0.000185	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—ALB—chronic obstructive pulmonary disease	7.9e-06	0.000184	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	7.77e-06	0.000181	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	7.72e-06	0.00018	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	7.7e-06	0.000179	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	7.59e-06	0.000177	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—NOS3—chronic obstructive pulmonary disease	7.56e-06	0.000176	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CTGF—chronic obstructive pulmonary disease	7.43e-06	0.000173	CbGpPWpGaD
Naproxen—ALB—Metabolism—CTGF—chronic obstructive pulmonary disease	7.39e-06	0.000172	CbGpPWpGaD
Naproxen—PTGS2—Disease—ERBB3—chronic obstructive pulmonary disease	7.08e-06	0.000165	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.02e-06	0.000163	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	6.93e-06	0.000161	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—HMOX1—chronic obstructive pulmonary disease	6.92e-06	0.000161	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—ALB—chronic obstructive pulmonary disease	6.88e-06	0.00016	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.85e-06	0.000159	CbGpPWpGaD
Naproxen—AKR1C3—Disease—IL6—chronic obstructive pulmonary disease	6.85e-06	0.000159	CbGpPWpGaD
Naproxen—ALB—Metabolism—CYP1A2—chronic obstructive pulmonary disease	6.81e-06	0.000159	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GSTT1—chronic obstructive pulmonary disease	6.71e-06	0.000156	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GCLC—chronic obstructive pulmonary disease	6.63e-06	0.000154	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—NOS3—chronic obstructive pulmonary disease	6.58e-06	0.000153	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—GSTM1—chronic obstructive pulmonary disease	6.45e-06	0.00015	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—ALB—chronic obstructive pulmonary disease	6.42e-06	0.00015	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	6.36e-06	0.000148	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	6.24e-06	0.000145	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	6.18e-06	0.000144	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—NOS3—chronic obstructive pulmonary disease	6.14e-06	0.000143	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.11e-06	0.000142	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CTGF—chronic obstructive pulmonary disease	6.05e-06	0.000141	CbGpPWpGaD
Naproxen—PTGS2—Disease—NOS2—chronic obstructive pulmonary disease	5.9e-06	0.000138	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GSTT1—chronic obstructive pulmonary disease	5.73e-06	0.000133	CbGpPWpGaD
Naproxen—ALB—Hemostasis—VEGFA—chronic obstructive pulmonary disease	5.72e-06	0.000133	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.71e-06	0.000133	CbGpPWpGaD
Naproxen—ALB—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.68e-06	0.000132	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GCLC—chronic obstructive pulmonary disease	5.66e-06	0.000132	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.63e-06	0.000131	CbGpPWpGaD
Naproxen—ALB—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.6e-06	0.00013	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	5.57e-06	0.00013	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	5.28e-06	0.000123	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.25e-06	0.000122	CbGpPWpGaD
Naproxen—ALB—Hemostasis—TGFB1—chronic obstructive pulmonary disease	5.25e-06	0.000122	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—TP53—chronic obstructive pulmonary disease	5.24e-06	0.000122	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—ALB—chronic obstructive pulmonary disease	5.24e-06	0.000122	CbGpPWpGaD
Naproxen—ALB—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.22e-06	0.000122	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CTGF—chronic obstructive pulmonary disease	5.17e-06	0.00012	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—NOS3—chronic obstructive pulmonary disease	5.01e-06	0.000117	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.97e-06	0.000116	CbGpPWpGaD
Naproxen—PTGS2—Disease—SERPINE1—chronic obstructive pulmonary disease	4.97e-06	0.000116	CbGpPWpGaD
Naproxen—ALB—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.95e-06	0.000115	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.79e-06	0.000112	CbGpPWpGaD
Naproxen—PTGS2—Disease—NOS3—chronic obstructive pulmonary disease	4.75e-06	0.000111	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.65e-06	0.000108	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.58e-06	0.000107	CbGpPWpGaD
Naproxen—ALB—Hemostasis—TP53—chronic obstructive pulmonary disease	4.32e-06	0.000101	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.27e-06	9.95e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—ALB—chronic obstructive pulmonary disease	4.16e-06	9.68e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	4.05e-06	9.43e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—NOS3—chronic obstructive pulmonary disease	3.98e-06	9.26e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.97e-06	9.25e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.92e-06	9.12e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.65e-06	8.5e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.46e-06	8.06e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—ALB—chronic obstructive pulmonary disease	3.38e-06	7.88e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—NOS3—chronic obstructive pulmonary disease	3.23e-06	7.53e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—NOS3—chronic obstructive pulmonary disease	3.22e-06	7.49e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—TGFB1—chronic obstructive pulmonary disease	3.14e-06	7.31e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—EGFR—chronic obstructive pulmonary disease	3.08e-06	7.17e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ALB—chronic obstructive pulmonary disease	2.75e-06	6.41e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—NOS3—chronic obstructive pulmonary disease	2.63e-06	6.13e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—IL6—chronic obstructive pulmonary disease	2.37e-06	5.51e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ALB—chronic obstructive pulmonary disease	2.35e-06	5.48e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—NOS3—chronic obstructive pulmonary disease	2.25e-06	5.24e-05	CbGpPWpGaD
